Sun Pharma to acquire 100% of Innovcare Lifesciences for about Rs 271.2 cr

Listed Co AcquisitionStrategic Transactions View source PDF

SUNPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+1.4%1-day move

₹1840.50

prior close

₹1845.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.6-0.3-0.4-0.2+1.4+1.8+1.1+1.7+1.4+1.7+5.6+5.6——

Up moveDown movePending

AI summary

Sun Pharma will acquire 100% of Mumbai-based Innovcare Lifesciences for about Rs 271.2 crores in cash. Innovcare markets and distributes pharma, nutraceutical and cosmeceutical products in India, with FY26 revenue of Rs 94.06 crores, up from Rs 86.09 cr in FY25 and Rs 80.93 cr in FY24. The deal is not a related party transaction, needs no regulatory approvals, and is expected to close by 31 July 2026. Sun Pharma called it a strategic investment to strengthen its product portfolio.

Likely market impact

Strengthens Sun Pharma's domestic portfolio in nutraceuticals and cosmeceuticals. All-cash deal with no regulatory hurdles. Modest scale.